NVS - Novartis AG

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Novartis reports Q3 earnings boosted by strong sales of key drugs and raises FY23 outlook
• Novartis Q3 2023 Earnings Preview
• POINT Biopharma trades through deal price with Eli Lilly
• Novartis spinoff Sandoz makes public debut
• Novartis said to be considering a partial sale of radiopharma unit
• Drugmakers comply with Medicare pricing talks despite lawsuits
• GLP-1 drug developer Carmot Therapeutics reportedly mulling IPO or buyout
• Teva names Novartis exec to lead US commercial business
• Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say
• Novartis readies Sandoz spinoff for trading on Oct. 4
• BeiGene regains full rights to cancer therapy from Novartis
• AARP weighs in on Merck case challenging Medicare drug negotiation
• Novartis shareholders approve 100% spinout of Sandoz unit
• EMA advisors recommend many new meds at latest meeting
• Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara
• Bausch + Lomb to raise debt to finance Novartis deal
• Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates
• AbbVie immunology chief to lead Novartis commercial operations
• Why is big pharma unmoved despite Medicare pricing threat?
• Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag